Revance Therapeutics (NASDAQ:RVNC) released its quarterly earnings data on Sunday. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.
RVNC traded down $0.98 on Tuesday, hitting $25.98. The company had a trading volume of 62,717 shares, compared to its average volume of 425,713. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.07 and a quick ratio of 7.01. Revance Therapeutics has a 52-week low of $11.78 and a 52-week high of $34.62. The stock has a fifty day simple moving average of $28.31 and a 200-day simple moving average of $26.92. The firm has a market capitalization of $1.73 billion, a P/E ratio of -5.70 and a beta of 1.42.
Several equities research analysts have weighed in on RVNC shares. Barclays increased their price target on shares of Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Monday, October 26th. Zacks Investment Research lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 12th. Mizuho boosted their price target on Revance Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC increased their price objective on Revance Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, January 8th. Finally, HC Wainwright lifted their price objective on Revance Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Revance Therapeutics has an average rating of “Buy” and a consensus price target of $32.88.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.
Featured Article: How to calculate the annual rate of depreciation
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.